Edouard Auclin1, Camille Bourillon2, Eleonora De Maio3, Marie Agnes By4, Sofiane Seddik5, Laure Fournier2, Marie Auvray1, Antoine Dautruche1, Yann-Alexandre Vano6, Constance Thibault1, Florence Joly5, Laurent Brunereau4, Carlos Gomez-Roca3, Christine Chevreau5, Reza Elaidi7, Stéphane Oudard8. 1. Oncology Department, European Georges Pompidou Hospital, René Descartes University, Paris, France. 2. Radiology Department, European Georges Pompidou Hospital, René Descartes University, Paris, France. 3. Oncology Department, Institut Universitaire du Cancer de Toulouse (IUCT)/Institut Claudius Regaud, Toulouse, France. 4. Oncology Department, Centre Hospitalier Bretonneau, Tours, France. 5. Oncology Department, Centre François Baclesse, Caen, France. 6. Oncology Department, European Georges Pompidou Hospital, René Descartes University, Paris, France; INSERM UMRS 1138, Cancer, Immune Control and Escape, Cordeliers Research Centre, Paris, France; Université Paris-Descartes, Sorbonne, Paris, France. 7. Oncology Department, European Georges Pompidou Hospital, René Descartes University, Paris, France; Association pour la Recherche sur les Thérapeutiques Innovantes en Cancérologie, Paris, France. 8. Oncology Department, European Georges Pompidou Hospital, René Descartes University, Paris, France; Association pour la Recherche sur les Thérapeutiques Innovantes en Cancérologie, Paris, France; U790 PARCC, European Georges Pompidou Hospital, René Descartes University, Paris, France. Electronic address: stephane.oudard@aphp.fr.
Abstract
BACKGROUND: The objective of the study was to assess the prognostic role of skeletal muscle index (SMI) in metastatic renal cell carcinoma (mRCC) patients treated with everolimus, and its effect of on everolimus-induced toxicity. PATIENTS AND METHODS: Consecutive mRCC patients treated with everolimus between February 2007 and November 2014 underwent computed tomography scans at a single center performed by the same radiologist. SMI was assessed before everolimus treatment using the L3 cross-sectional area. Overall survival (OS) was analyzed according to SMI value. Results were adjusted using the International Metastatic Database Consortium (IMDC) prognostic group, body mass index (BMI), and/or number of previous tyrosine kinase inhibitor lines (NPL). RESULTS: One hundred twenty-four mRCC patients (mean age, 60.21 years) were treated with everolimus as second- or third-line (82.3%) or > third-line (17.7%) therapy. Most patients (87.9%) had clear cell carcinoma. IMDC prognostic group was "favorable" (32.3%), "intermediate" (50%), or "poor" (17.7%). Median SMI was 40.75. OS was longer in patients from the highest versus lowest SMI tercile: 21.9 versus 10 months (P = .002). Continuous SMI at baseline was not significantly associated with OS after adjustment for IMDC prognostic group, BMI, or NPL but the highest versus lowest SMI tercile was an independent prognostic factor in multivariate analysis (P = .025). There was no difference in everolimus toxicity between SMI tercile groups. CONCLUSION: SMI was an independent prognostic factor for mRCC patients treated with everolimus. Whether this provides additional prognostic value to IMDC criteria needs to be confirmed in a larger cohort. SMI does not seem to be predictive of everolimus-induced toxicity.
BACKGROUND: The objective of the study was to assess the prognostic role of skeletal muscle index (SMI) in metastatic renal cell carcinoma (mRCC) patients treated with everolimus, and its effect of on everolimus-induced toxicity. PATIENTS AND METHODS: Consecutive mRCC patients treated with everolimus between February 2007 and November 2014 underwent computed tomography scans at a single center performed by the same radiologist. SMI was assessed before everolimus treatment using the L3 cross-sectional area. Overall survival (OS) was analyzed according to SMI value. Results were adjusted using the International Metastatic Database Consortium (IMDC) prognostic group, body mass index (BMI), and/or number of previous tyrosine kinase inhibitor lines (NPL). RESULTS: One hundred twenty-four mRCC patients (mean age, 60.21 years) were treated with everolimus as second- or third-line (82.3%) or > third-line (17.7%) therapy. Most patients (87.9%) had clear cell carcinoma. IMDC prognostic group was "favorable" (32.3%), "intermediate" (50%), or "poor" (17.7%). Median SMI was 40.75. OS was longer in patients from the highest versus lowest SMI tercile: 21.9 versus 10 months (P = .002). Continuous SMI at baseline was not significantly associated with OS after adjustment for IMDC prognostic group, BMI, or NPL but the highest versus lowest SMI tercile was an independent prognostic factor in multivariate analysis (P = .025). There was no difference in everolimus toxicity between SMI tercile groups. CONCLUSION: SMI was an independent prognostic factor for mRCC patients treated with everolimus. Whether this provides additional prognostic value to IMDC criteria needs to be confirmed in a larger cohort. SMI does not seem to be predictive of everolimus-induced toxicity.